Navigation Links
Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Date:9/14/2007

Event for Congressional Members and Staff Will Focus on Advances in

Research and Treatment of Lung Cancer in Women

SEATTLE, Sept. 14 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX:), along with the Society for Women's Health Research, the Lung Cancer Alliance and others, will sponsor a panel discussion entitled "Lung Cancer: Being Female Matters to Research," on Capitol Hill to discuss advances in the research and treatment of lung cancer in women on Monday, September 17.

CTI has been conducting clinical trials of its investigational drug, XYOTAX(TM), researching how estrogen levels affect a woman's response to treatment for lung cancer. Data collected from recent XYOTAX trials suggests that estrogen levels may alter the effectiveness of cancer treatment, and that women with higher levels of estrogen had a lower rate of survival in cases of lung cancer.

The event will be held in room B-340 of the Rayburn House Office Building from noon to 1:30 p.m. Speakers will include Laurie Fenton Ambrose, President of the Lung Cancer Alliance, Joan H. Schiller, M.D., Chief of Hematology and Oncology at the University of Texas Southwestern Medical Center and Deputy Director of Simmons Comprehensive Cancer Center, and Jill M. Siegfried, Ph.D., Professor and Vice Chair of Pharmacology at the University of Pittsburgh School of Medicine and co-Director of the Lung and Esophageal Cancer Program at the University of Pittsburgh Cancer Institute (UPCI).

Women and Lung Cancer

Lung cancer is the number one cancer killer of women in the United States -- more than breast and ovarian cancers combined. The American Cancer Society estimates that in 2007 there will be approximately 213,490 new cases of lung cancer in the United States -- up 22 percent from 2006. Of those new cases, 98,620 will be among women -- up 20 percent from a year ago. One in 16 women will develop lung cancer in their lifetime.

"Gende
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Analyzers Offer Point-of-Care Lipid Panels
5. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
6. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
7. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 MC Medical, a subsidiary of ... Columbus, OH medical device company, have ... laparoscopic and robotic visualization system in Japan ... sale in Japan in the latter ... and an extensive product portfolio in endoscopic surgery market in ...
(Date:8/22/2014)... , Aug. 22, 2014   Zacks Equity Research highlights ... of the Day and Panera (Nasdaq: PNRA - Free Report ... Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free ... Shire (Nasdaq: SHPG - Free Report ). Here ... Bull of the Day : The biotech bull ...
(Date:8/22/2014)... LA JOLLA , Cali ., Aug. ... Annual International Papillomavirus Conference shows that a therapy being developed ... including the two that cause 70 percent of all cervical ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker , Ph.D., who presented the findings at ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... Frankfurt am Main Emergency Medical Services (EMS) ... MASI ), the inventor of rainbow® Pulse CO-Oximetry™, rainbow ... Perfusion pulse oximetry, today jointly announced that every EMS ... equipped with a Masimo Rad-57® Pulse CO-Oximeter—making carbon monoxide ...
... Aug. 26 Cardioxyl Pharmaceuticals, Inc. , a ... of cardiovascular disease, today announced that it has initiated ... candidate, CXL-1020, for the treatment of patients with acute ... for patients at the time of discharge from U.S. ...
Cached Medicine Technology:Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles 2Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles 3Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles 4Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles 5Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 2Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 3Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 4
(Date:8/23/2014)... 23, 2014 A team of New York ... longer when preceded by surgery and delivered by an experienced ... new study. Click here to read it now . ... cases of mesothelioma patients who underwent hemithoracic (one ... dose to the shape of a tumor. Patients who ...
(Date:8/23/2014)... Board of Directors voted on Monday, August 18th to approve ... for commercial and industrial properties. This was accomplished with ... in Carmel, California. , This is a historical moment, ... the State of California has approved this technology for use ... can now be used as a sole source of water ...
(Date:8/23/2014)... TX (PRWEB) August 23, 2014 Youth ... of Texas. It’s no different in Houston, TX. Substance ... are falling victim to drug and alcohol dependency in ... are looking to beat substance abuse, but don’t know ... juvenile treatment facility can be a challenge because most ...
(Date:8/22/2014)... 23, 2014 The IT manager of ... hosting for several years. He has recently announced that ... hosting suppliers in 2014. , GoDaddy is a popular ... features and great hosting solutions at affordable rates. It ... for shared hosting plans depend on the length of ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 AWeber, ... services that currently helps more than 120,000 small ... caught the attention of Shane Michaels, prompting an investigative ... crucial element for any online marketing campaign, despite what ... in the marketing world,” reports Michaels. “AWeber is a ...
Breaking Medicine News(10 mins):Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2
... Mass., Nov. 25 Gene Network Sciences, Inc.,(GNS) ... company, Fina,Technologies, Inc. (Fina) to leverage its proprietary ... new arena -- that of,quantitative financial trading and ... raw clinical and genomics data to identify drug,targets, ...
... Season , , ROSELAND, N.J., ... during the busy holiday season. Unfortunately many get drawn into buying ... At airports, it,s easy to wind up eating unhealthy foods ... a rush or have time to spend before a flight, you ...
... Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that the ... Health Care Conference on December 3, 2008 at 2:30,p.m. Eastern ... Hotel in,New York City. Jack Lief, Arena,s President and Chief ... including its clinical,development and discovery programs. , ...
... /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian ... of drug products delivered to and through the skin, ... and development subsidiary, has signed a research and development ... develops and markets skin care products. Financial details of ...
... 25 Hillenbrand, Inc.,(NYSE: HI ) -- ... United States,District Court in the Southern District of Texas ... denied in,two previously disclosed antitrust lawsuits against Batesville Casket ... As previously reported, a purported consumer ...
... WELLINGTON, Fla., Nov. 25 The Quantum Group,Inc. ... solutions provider for,the healthcare industry, announced today that ... approval and a Certificate,of Authority from the State ... RASI has been established to provide administrative ...
Cached Medicine News:Health News:Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce 2Health News:Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce 3Health News:Nutritionist Claudia Gonzalez Shares Tips for Eating Well On-the-Go During the Busy Holiday Rush 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company 2Health News:Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company 3Health News:Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation 2Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 2Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 3Health News:The Quantum Group Announces State Approval of TPA Application for Subsidiary Company Renaissance Administrative Solutions, Inc. 4
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... is the first ... to offer two kinds ... and taurine. Cleans, rinses, ... and conditions any soft ...
Medicine Products: